The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...